CompletedPhase 1NCT03830125

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

Studying Idiopathic pulmonary fibrosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Bridge Biotherapeutics, Inc.
Principal Investigator
Jeong-Hyun Ryou, M.D., Ph.D.
Bridge Biotherapeutics, Inc.
Intervention
BBT-877, Single dose(drug)
Enrollment
88 enrolled
Eligibility
19-55 years · All sexes
Timeline
2019 – 2019

Study locations (1)

Collaborators

KCRN Research, LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03830125 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary fibrosis →

← Back to all trials